170 related articles for article (PubMed ID: 8501821)
1. A recombinant form of Pseudomonas exotoxin A containing transforming growth factor alpha near its carboxyl terminus for the treatment of bladder cancer.
Theuer CP; FitzGerald DJ; Pastan I
J Urol; 1993 Jun; 149(6):1626-32. PubMed ID: 8501821
[TBL] [Abstract][Full Text] [Related]
2. Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin.
Wang QC; Pai LH; Debinski W; FitzGerald DJ; Pastan I
Cancer Res; 1993 Oct; 53(19):4588-94. PubMed ID: 8402632
[TBL] [Abstract][Full Text] [Related]
3. In vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity.
Sarosdy MF; Hutzler DH; Yee D; von Hoff DD
J Urol; 1993 Dec; 150(6):1950-5. PubMed ID: 8230543
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effect of a fusion protein from transforming growth factor alpha and Pseudomonas exotoxin on rat and human bladder carcinoma cells in vitro.
Kameyama S; Kawamata H; Pastan I; Oyasu R
J Cancer Res Clin Oncol; 1994; 120(9):507-12. PubMed ID: 8045915
[TBL] [Abstract][Full Text] [Related]
5. A recombinant form of Pseudomonas exotoxin directed at the epidermal growth factor receptor that is cytotoxic without requiring proteolytic processing.
Theuer CP; FitzGerald D; Pastan I
J Biol Chem; 1992 Aug; 267(24):16872-7. PubMed ID: 1512230
[TBL] [Abstract][Full Text] [Related]
6. Analysis of sequences required for the cytotoxic action of a chimeric toxin composed of Pseudomonas exotoxin and transforming growth factor alpha.
Kihara A; Pastan I
Bioconjug Chem; 1994; 5(6):532-8. PubMed ID: 7873657
[TBL] [Abstract][Full Text] [Related]
7. Biological activity of a transforming growth factor-alpha--Pseudomonas exotoxin fusion protein in vitro and in vivo.
Heimbrook DC; Stirdivant SM; Ahern JD; Balishin NL; Patrick DR; Edwards GM; Defeo-Jones D; FitzGerald DJ; Pastan I; Oliff A
J Ind Microbiol; 1991 Apr; 7(3):203-7. PubMed ID: 1367127
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts.
Heimbrook DC; Stirdivant SM; Ahern JD; Balishin NL; Patrick DR; Edwards GM; Defeo-Jones D; FitzGerald DJ; Pastan I; Oliff A
Proc Natl Acad Sci U S A; 1990 Jun; 87(12):4697-701. PubMed ID: 2352944
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha.
Schmidt M; Wels W
Br J Cancer; 1996 Sep; 74(6):853-62. PubMed ID: 8826849
[TBL] [Abstract][Full Text] [Related]
10. A transforming growth factor-alpha-Pseudomonas exotoxin hybrid protein undergoes pH-dependent conformational changes conducive to membrane interaction.
Sanyal G; Marquis-Omer D; Gress JO; Middaugh CR
Biochemistry; 1993 Apr; 32(13):3488-97. PubMed ID: 8461310
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas exotoxin: recombinant conjugates as therapeutic agents.
FitzGerald DJ; Pastan I
Biochem Soc Trans; 1992 Nov; 20(4):731-4. PubMed ID: 1487051
[No Abstract] [Full Text] [Related]
12. Heparin-binding transforming growth factor alpha-Pseudomonas exotoxin A. A heparan sulfate-modulated recombinant toxin cytotoxic to cancer cells and proliferating smooth muscle cells.
Mesri EA; Kreitman RJ; Fu YM; Epstein SE; Pastan I
J Biol Chem; 1993 Mar; 268(7):4853-62. PubMed ID: 8444864
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic activities of a fusion protein comprised of TGF alpha and Pseudomonas exotoxin.
Siegall CB; Xu YH; Chaudhary VK; Adhya S; Fitzgerald D; Pastan I
FASEB J; 1989 Dec; 3(14):2647-52. PubMed ID: 2556314
[TBL] [Abstract][Full Text] [Related]
14. Recombinant toxins.
Kreitman RJ; Pastan I
Adv Pharmacol; 1994; 28():193-219. PubMed ID: 8080817
[No Abstract] [Full Text] [Related]
15. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL.
Seetharam S; Chaudhary VK; FitzGerald D; Pastan I
J Biol Chem; 1991 Sep; 266(26):17376-81. PubMed ID: 1910044
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxins and recombinant toxins in the treatment of solid carcinomas.
Theuer CP; Pastan I
Am J Surg; 1993 Sep; 166(3):284-8. PubMed ID: 8368439
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells.
Kunwar S; Pai LH; Pastan I
J Neurosurg; 1993 Oct; 79(4):569-76. PubMed ID: 7692018
[TBL] [Abstract][Full Text] [Related]
18. Recombinant single-chain immunotoxins against T and B cell leukemias.
Kreitman RJ; Pastan I
Leuk Lymphoma; 1994 Mar; 13(1-2):1-10. PubMed ID: 8025511
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
Michaelis M; Bliss J; Arnold SC; Hinsch N; Rothweiler F; Deubzer HE; Witt O; Langer K; Doerr HW; Wels WS; Cinatl J
Clin Cancer Res; 2008 Oct; 14(20):6531-7. PubMed ID: 18927293
[TBL] [Abstract][Full Text] [Related]
20. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.
Kreitman RJ; Puri RK; Pastan I
Cancer Res; 1995 Aug; 55(15):3357-63. PubMed ID: 7614471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
